Periscope Capital’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Periscope Capital’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-178,393	Closed	-$1.79M	–	970
2022 Q3	$1.79M	Buy	178,393 +1,400	+0.8%	+$13.9K	0.05%	512
2022 Q2	$1.75M	Buy	176,993 +78,600	+80%	+$777K	0.05%	556
2022 Q1	$970K	Buy	98,393 +19,895	+25%	+$195K	0.03%	623
2021 Q4	$766K	Hold	78,498	–	–	0.02%	606
2021 Q3	$768K	Buy	+78,498	New	+$765K	0.02%	573

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Periscope Capital's EUCR Position: Q4 2022 in Review

Periscope Capital sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 178,393 shares — an estimated $1.79M sold.

Periscope Capital first reported a position in EUCR in Q3 2021 and held it in 5 quarters. The position peaked at $1.79M in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

Periscope Capital reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Periscope Capital sold 178,393 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $1.79M.
Periscope Capital first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q3 2021 and held it in 5 quarters.
Periscope Capital's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $1.79M in Q3 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on Periscope Capital's 13F filing for Q4 2022, filed 13 Feb 2023.